Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over-the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides OTC pharmaceutical cross-border procurement and distribution and e-commerce supply chain services. It also offers customs clearance, drugs en…
| Métrica | HKPD | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 11.9% | 57.4% | -45.5% |
| Operating Margin | -11.3% | -34.4% | +23.1% |
| Net Margin | -0.1% | -32.5% | +32.3% |
| FCF Margin | 2.5% | -12.6% | +15.1% |
| ROE | -0.5% | -39.2% | +38.6% |
| ROA | -0.3% | -30.9% | +30.7% |
| Current Ratio | 2.99 | 2.73 | +0.26 |
| Debt / Equity | 0.30 | 0.28 | +0.02 |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -0.3% | — |
| ✓Flujo de caja operativo positivo | $569,214 | −$394,330 |
| ✗Rentabilidad sobre activos al alza | -0.3% | 15.3% |
| ✓Caja operativa/activos supera al ROA | 6.0% | ROA -0.3% |
| ✗Menos deuda a largo plazo | 16.0% | 12.9% |
| ✓Mejor liquidez (ratio corriente) | 2.99 | 2.46 |
| ✗Sin aumentar el nº de acciones | 10M | 7M |
| ✗Margen bruto al alza | 11.9% | 21.3% |
| ✓Rotación de activos al alza | 2.16 | 1.93 |
| Calidad del negocio | FY25 |
|---|---|
| ✗Margen FCF > 10 % | 2.5% |
| ✗ROCE > 10 % | -35.1% |
| ✓Deuda neta/EBITDA < 3x | -0.5x |
| ✗Reinversión (I+D + capex) > 3 % de ventas | 0.3% |
Riesgo de quiebra (Altman Z 3.1): zona segura
Cellyan Biotechnology Co., Ltd cotiza a 0.11 USD y tiene una capitalización bursátil de $5M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud